^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    Imunace (teceleukin)

    i
    Other names: BG 8301, RO 23 6019 , S 6820, Bioleukin, Bioleukin IL-2
    Associations

    News

    Trials
    Company:
    Shionogi
    Drug class:
    IL-2 stimulant
    Related drugs:
    Associations

    News

    Trials
    4ms
    NCI-2018-01509: Autologous Tumor Infiltrating Lymphocytes MDA-TIL in Treating Patients With Recurrent or Refractory Ovarian Cancer, Colorectal Cancer, or Pancreatic Ductal Adenocarcinoma (clinicaltrials.gov)
    P2, N=60, Terminated, M.D. Anderson Cancer Center | Trial completion date: Jan 2025 --> Aug 2024 | Active, not recruiting --> Terminated | Trial primary completion date: Jan 2025 --> Aug 2024; Lack of Efficacy
    Trial completion date • Trial termination • Trial primary completion date
    |
    CD8 (cluster of differentiation 8) • CD28 (CD28 Molecule) • CD27 (CD27 Molecule)
    |
    cyclophosphamide • fludarabine IV • Imunace (teceleukin)
    10ms
    Lifileucel With Reduced Dose Fludarabine/Cyclophosphamide Lymphodepletion and Interleukin-2 for the Treatment of Patients With Unresectable or Metastatic Melanoma (clinicaltrials.gov)
    P2, N=12, Recruiting, University of Kansas Medical Center | Trial primary completion date: Nov 2024 --> Nov 2025
    Trial primary completion date • Metastases
    |
    cyclophosphamide • fludarabine IV • Amtagvi (lifileucel) • Imunace (teceleukin)
    12ms
    NCI-2018-01509: Autologous Tumor Infiltrating Lymphocytes MDA-TIL in Treating Patients With Recurrent or Refractory Ovarian Cancer, Colorectal Cancer, or Pancreatic Ductal Adenocarcinoma (clinicaltrials.gov)
    P2, N=60, Active, not recruiting, M.D. Anderson Cancer Center | N=27 --> 60 | Trial primary completion date: Jan 2024 --> Jan 2025
    Enrollment change • Trial primary completion date
    |
    CD8 (cluster of differentiation 8) • CD28 (CD28 Molecule) • CD27 (CD27 Molecule)
    |
    CD8 expression • CD28 expression
    |
    cyclophosphamide • fludarabine IV • Imunace (teceleukin)
    1year
    Lifileucel With Reduced Dose Fludarabine/Cyclophosphamide Lymphodepletion and Interleukin-2 for the Treatment of Patients With Unresectable or Metastatic Melanoma (clinicaltrials.gov)
    P2, N=12, Recruiting, University of Kansas Medical Center | Not yet recruiting --> Recruiting
    Enrollment open
    |
    cyclophosphamide • fludarabine IV • Amtagvi (lifileucel) • Imunace (teceleukin)
    1year
    Lifileucel With Reduced Dose Fludarabine/Cyclophosphamide Lymphodepletion and Interleukin-2 for the Treatment of Patients With Unresectable or Metastatic Melanoma (clinicaltrials.gov)
    P2, N=12, Not yet recruiting, University of Kansas Medical Center
    New P2 trial
    |
    cyclophosphamide • fludarabine IV • Amtagvi (lifileucel) • Imunace (teceleukin)
    4years
    Gene Modified Immune Cells (IL13Ralpha2 CAR T Cells) After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma (clinicaltrials.gov)
    P1, N=24, Recruiting, Jonsson Comprehensive Cancer Center | Suspended --> Recruiting
    Clinical • Enrollment open • CAR T-Cell Therapy
    |
    BRAF (B-raf proto-oncogene) • CD123 (Interleukin 3 Receptor Subunit Alpha) • IL2 (Interleukin 2)
    |
    BRAF mutation • BRAF V600
    |
    fludarabine IV • Imunace (teceleukin) • MB-101 • cyclophosphamide intravenous
    over4years
    Gene Modified Immune Cells (IL13Ralpha2 CAR T Cells) After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma (clinicaltrials.gov)
    P1, N=24, Suspended, Jonsson Comprehensive Cancer Center | Recruiting --> Suspended
    Clinical • Trial suspension • CAR T-Cell Therapy
    |
    BRAF (B-raf proto-oncogene) • CD123 (Interleukin 3 Receptor Subunit Alpha) • IL2 (Interleukin 2)
    |
    BRAF mutation • BRAF V600
    |
    fludarabine IV • Imunace (teceleukin) • MB-101 • cyclophosphamide intravenous
    5years
    Gene Modified Immune Cells (IL13Ralpha2 CAR T Cells) After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma (clinicaltrials.gov)
    P1, N=24, Recruiting, Jonsson Comprehensive Cancer Center | Not yet recruiting --> Recruiting
    Clinical • Enrollment open • CAR T-Cell Therapy
    |
    BRAF (B-raf proto-oncogene) • CD123 (Interleukin 3 Receptor Subunit Alpha) • IL2 (Interleukin 2)
    |
    BRAF mutation • BRAF V600
    |
    fludarabine IV • Imunace (teceleukin) • MB-101 • cyclophosphamide intravenous